Biovie is trading 5.8% down at $1.31 on October 12, 2026, with no clear company-specific catalyst identified. - The company’s investor-news page lists its latest release as the September 15 Phase 2 Long COVID trial results. - Provided market context shows only modestly mixed index moves, with no broad decline greater than 0.5% to explain the drop. - The price and percentage are from the supplied price context.